Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I G M Lancisi G Salesi
- Address
- lock Available on a paid plan
Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I G M Lancisi G Salesi
This comprehensive academic medical center demonstrates exceptional expertise in hematologic malignancies and oncology research, with a strong focus on precision medicine approaches and innovative therapeutic combinations. The institution plays a leading role in advancing treatment paradigms for complex blood disorders and solid tumors through participation in international multi-center clinical trials.
- Acute Leukemia and Myelodysplastic Syndromes: Advanced trials investigating novel combinations including venetoclax, targeted immunotherapies, and minimal residual disease-guided treatment strategies for AML, ALL, and MDS
- Multiple Myeloma and Lymphoproliferative Disorders: Comprehensive research programs evaluating next-generation therapies including teclistamab, isatuximab, carfilzomib combinations, and stem cell transplantation protocols
- Solid Tumor Oncology: Innovative trials in colorectal cancer, lung cancer, and other malignancies featuring biomarker-driven approaches, immunotherapy combinations, and liquid biopsy-guided interventions
- Pediatric Oncology and Rare Diseases: Specialized programs in neuroblastoma, medulloblastoma, Ewing sarcoma, and Langerhans cell histiocytosis with risk-adapted multimodal treatment strategies
The center maintains active research portfolios across diverse therapeutic areas including pulmonary fibrosis, neonatal hypoxic-ischemic encephalopathy, cardiovascular interventions, and inflammatory bowel disease. The institution's commitment to translational medicine is evidenced by extensive biomarker studies, minimal residual disease monitoring, and circulating tumor DNA analysis, positioning it at the forefront of personalized cancer care and precision therapeutics in Italy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 13 therapeutic areas and 15 of 102 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 95 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 29 by active trials.
lock +28 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I G M Lancisi G Salesi
lock Showing 1 of 45 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer - GeparPiPPa | GBG Forschungs GmbH | Phase II | Recruiting | Dec 2022 | — |
IMP list
lock Showing 1 of 102 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 7 | Unknown | 2019-10-30 | 2024-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.